Australian Centre for Accelerating Diabetes Innovations (ACADI)
Vision: The Australian Centre for Accelerating Diabetes Innovations (ACADI) aims to benefit people with diabetes at each stage from diagnosis to its devastating complications. Led out of the University of Melbourne, ACADI will deliver novel interventions for timely diagnosis, prevention and treatment of diabetes and its complications with the access to clinical evaluation, leadership and networks, research commercialisation experience and workforce training. ACADI's design responds to key barriers slowing Australian development of innovations.
Globally, almost 500 million people live with diabetes with 51% more people expected by 2045. ACADI is uniquely positioned to improve the lives of millions of people in Australia and overseas, and to set Australia as a global leader in innovations for diabetes.
ACADI creates a unique opportunity to build a national multi-sector collaboration between 70 partners spanning clinical, research, industry and community organisations across Australia. Over its four-year term, ACADI will deliver at least 18 projects which progress a series of therapeutic, device, in vitro diagnostic and digital health products towards practical use. It will seek strategic input from national experts and consumers, including an Indigenous Advisory Group. A customised Training Program will address skills gaps in industry, academia and clinical sectors; mentor emerging business and clinical leaders and train a pipeline of PhDs and Post Docs in translational research.
ACADI Centre Director: Associate Professor Elif Ekinci
ACADI Centre Deputy Director: Professor David O'Neal
Website: ACADI | LinkedIn: ACADI_Centre | Twitter: @ACADI_Centre #ACADI
University of Melbourne
Website: University of Melbourne | LinkedIn: University of Melbourne | Twitter: @unimelbMDHS
Research Centre Partners: University of Melbourne; 3Aim Solutions; Abbott Australasia Pty Ltd; Abbott Diabetes Care; Applied Infrared Sensing; Austin Health; Australian Diabetes Educators Association; Australian Diabetes Society; Australian Kidney Foundation; Australian National University; Bayer Australia Ltd; Blackmores; Boehringer Ingelheim-Lilly Diabetes Alliance; Bolton Clarke; Cairns Hospital; Canberra Health Services; Compumedics Limited; CSL; Curve Tomorrow; Deakin University; Dexcom; Diabetes Australia; Diabetes Research Western Australia; Diabetes Victoria; Dimerix Bioscience Pty Ltd; Endocrinology Melbourne; Flinders University; Goulburn Valley Health; Harry Perkins Institute of Medical Research; Inside Public Relations; Insulet Australia Pty Ltd; JDRF Australia (Juvenile Diabetes Research Foundation); KeyLead Health; Khondrion BV; Lilly Australia Pty Ltd; Mater Research; Medtronic Diabetes; Menzies School of Health Research; Monash University; Murdoch Children’s Research Institute; NHMRC Clinical Trials Centre, University of Sydney; Northern Health; Novo Nordisk Pharmaceuticals Pty Ltd; Percusense; Perspicacite; Princess Alexandra Hospital; Proteomics International; Queensland University of Technology; Ray Kelly Fitness; RMIT University; Royal Melbourne Hospital; Royal North Shore Hospital; Sanofi; South Western Sydney LHD (SWSLHD); Southern Adelaide Local Health Network; St Vincent’s Hospital Melbourne; St Vincent’s Hospital Sydney; St Vincent’s Institute of Medical Research; University of Adelaide; University of California Irvine; University of New South Wales; University of Oxford; University of Queensland; University of South Australia; University of Sydney; University of Tasmania; University of the Sunshine Coast Australia; University of Western Australia; Western Health; Western Sydney University.